Title: Phase II study of rhizoxin in squamous cell head and neck cancer
Authors: Verweij, J ×
Wanders, J
Gil, T
Schöffski, Patrick
Catimel, G
teVelde, A
deMulder, PHM #
Issue Date: Feb-1996
Publisher: Harcourt Publishers
Series Title: British Journal of Cancer vol:73 issue:3 pages:400-402
Abstract: To lest the anti-tumour activity of rhizoxin in recurrent and/or metastatic squamous cell head and neck cancer, we performed a phase II study. Eligibility required histologically proven squamous cell head and neck cancer. Patients could only have received one prior chemotherapy. Patients were entered if WHO PS was less than or equal to 2 and organ functions were normal. Treatment consisted of rhizoxin 1.5-2.0 mg m(-2) i.v. bolus injection once every 3 weeks. Thirty-two patients entered the study. All were eligible, 31 were evaluable for toxicity and 25 for response. Toxicity mainly consisted of pain at the tumour site and leucocytopenia. Mild asthenia and stomatitis were also observed. Two objective partial responses, lasting 7.5 and 3.5 months, were seen. Rhizoxin at this dose and schedule has minor activity in recurrent and!or metastatic squamous cell head and neck cancer.
ISSN: 0007-0920
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Experimental Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science